[go: up one dir, main page]

TR200003455T2 - Kemik dayanıklılığını ve sertliğini arttırmak ve kırıkları azaltmak için yöntem - Google Patents

Kemik dayanıklılığını ve sertliğini arttırmak ve kırıkları azaltmak için yöntem

Info

Publication number
TR200003455T2
TR200003455T2 TR2000/03455T TR200003455T TR200003455T2 TR 200003455 T2 TR200003455 T2 TR 200003455T2 TR 2000/03455 T TR2000/03455 T TR 2000/03455T TR 200003455 T TR200003455 T TR 200003455T TR 200003455 T2 TR200003455 T2 TR 200003455T2
Authority
TR
Turkey
Prior art keywords
stiffness
spine
fracture
fractures
bone strength
Prior art date
Application number
TR2000/03455T
Other languages
English (en)
Inventor
M. Hock Janet
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200003455(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200003455T2 publication Critical patent/TR200003455T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Bu bulus bir paratiroid hormon uygulamak suretiyle kemik dayanikligini ve/veya sertligini arttirmak ve/veya kemik kirilma olasiligini ve/veya agirligini azaltmak için yönteme iliskindir. Yöntem osteoporosis riskiyle karsi karsiya veya bu hastaliga maruz bir insanin omurga veya kalçasi gibi potansiyel veya aktüel bir travma noktasinda kemigin dayaniklilik veya sertligini arttirmak için bir yönteme iliskindir. Bulusun yöntemi omurga kirigi olasiligini, birden fazla omurga kirigi olasiligini, omurga kiriginin agirligini ve/veya omurga kirigi disindaki kirik olasiligini düsürür.
TR2000/03455T 1998-08-19 1999-08-19 Kemik dayanıklılığını ve sertliğini arttırmak ve kırıkları azaltmak için yöntem TR200003455T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
TR200003455T2 true TR200003455T2 (tr) 2001-06-21

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03455T TR200003455T2 (tr) 1998-08-19 1999-08-19 Kemik dayanıklılığını ve sertliğini arttırmak ve kırıkları azaltmak için yöntem

Country Status (32)

Country Link
US (2) US6977077B1 (tr)
EP (3) EP2266598B1 (tr)
JP (5) JP2002523375A (tr)
KR (1) KR100454207B1 (tr)
CN (1) CN1205997C (tr)
AR (1) AR033639A1 (tr)
AT (1) ATE231000T1 (tr)
AU (1) AU746277B2 (tr)
BR (1) BR9909445A (tr)
CA (1) CA2325371C (tr)
CO (1) CO5130020A1 (tr)
CY (2) CY1113343T1 (tr)
CZ (1) CZ301017B6 (tr)
DE (2) DE15152726T1 (tr)
DK (4) DK1059933T3 (tr)
DZ (1) DZ2873A1 (tr)
EA (1) EA003362B1 (tr)
ES (4) ES2393200T3 (tr)
HR (1) HRP20000755A2 (tr)
HU (2) HU1200430D0 (tr)
ID (1) ID29039A (tr)
IL (2) IL138829A0 (tr)
MY (1) MY129227A (tr)
NO (2) NO323984B1 (tr)
NZ (1) NZ507056A (tr)
PE (1) PE20001089A1 (tr)
PL (1) PL201688B1 (tr)
PT (4) PT2907522T (tr)
TR (1) TR200003455T2 (tr)
TW (1) TW576747B (tr)
UA (1) UA72205C2 (tr)
WO (1) WO2000010596A1 (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
CA2387693A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
WO2003059291A2 (en) * 2002-01-10 2003-07-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
RU2006108557A (ru) * 2003-09-19 2007-09-27 Пфайзер Продактс Инк. (Us) Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения)
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
JP5007427B2 (ja) 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
JP2008540522A (ja) * 2005-05-11 2008-11-20 ユニジーン・ラボラトリーズ・インコーポレーテッド 骨の形成および保存を促進するための方法
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
ES2733276T3 (es) 2007-04-13 2019-11-28 Kuros Biosurgery Ag Sellante polimérico para tejidos
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
EP2217260B1 (en) * 2007-12-04 2016-11-09 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
WO2009083544A2 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
NZ617397A (en) 2009-09-09 2015-02-27 Asahi Kasei Pharma Corp Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
KR20150116467A (ko) 2011-06-07 2015-10-15 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN108601833B (zh) * 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
WO2018144719A1 (en) * 2017-02-01 2018-08-09 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
WO2019059302A1 (ja) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
CN119258199A (zh) 2018-10-29 2025-01-07 旭化成制药株式会社 特立帕肽或其盐在骨质疏松症治疗和/或预防剂的制备中的应用
WO2021030222A1 (en) 2019-08-09 2021-02-18 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
CA2205959A1 (en) * 1994-12-19 1996-06-27 Michael Chorev Continuous low-dose administration of parathyroid hormone or its agonist
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
CZ182297A3 (cs) * 1994-12-22 1998-01-14 Astra Aktiebolag Terapeutický přípravek pro inhalaci obsahující parathyroidní hormon, PTH
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
CZ298701B6 (cs) * 1997-09-09 2007-12-27 F. Hoffman-La Roche Ag Lécivo pro hojení kostí a reparaci zlomenin
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
JP2017190332A (ja) 2017-10-19
DZ2873A1 (fr) 2003-12-15
PE20001089A1 (es) 2000-11-04
ES2549551T1 (es) 2015-10-29
TW576747B (en) 2004-02-21
EP2266598A1 (en) 2010-12-29
PT2907522T (pt) 2017-10-23
HU230697B1 (hu) 2017-09-28
EP2907522A1 (en) 2015-08-19
AR033639A1 (es) 2004-01-07
CY1119552T1 (el) 2018-03-07
CN1205997C (zh) 2005-06-15
HK1212602A1 (en) 2016-06-17
HK1030545A1 (en) 2001-05-11
IL138829A (en) 2011-01-31
NO20072983L (no) 2000-11-24
BR9909445A (pt) 2000-12-12
US7163684B2 (en) 2007-01-16
ID29039A (id) 2001-07-26
JP2015028065A (ja) 2015-02-12
CN1308545A (zh) 2001-08-15
MY129227A (en) 2007-03-30
WO2000010596A1 (en) 2000-03-02
PT1059933E (pt) 2003-06-30
NO323984B1 (no) 2007-07-30
JP2014139220A (ja) 2014-07-31
DK2907522T1 (da) 2015-10-19
NZ507056A (en) 2003-10-31
DK1059933T3 (da) 2003-04-07
CZ301017B6 (cs) 2009-10-14
CA2325371C (en) 2004-08-17
CA2325371A1 (en) 2000-03-02
NO20005947D0 (no) 2000-11-24
DK2266598T3 (en) 2017-05-15
EP1059933A1 (en) 2000-12-20
ATE231000T1 (de) 2003-02-15
HUP0101594A2 (hu) 2001-11-28
CY1113343T1 (el) 2016-06-22
PT1769804E (pt) 2012-11-13
CO5130020A1 (es) 2002-02-27
PL343595A1 (en) 2001-08-27
HK1102496A1 (en) 2007-11-23
CZ20004134A3 (cs) 2001-08-15
AU746277B2 (en) 2002-04-18
JP2002523375A (ja) 2002-07-30
US20050197294A1 (en) 2005-09-08
EA003362B1 (ru) 2003-04-24
EP1059933B1 (en) 2003-01-15
ES2621653T3 (es) 2017-07-04
ES2190244T3 (es) 2003-07-16
ES2549551T3 (es) 2017-11-27
EP2907522B1 (en) 2017-08-02
JP6177718B2 (ja) 2017-08-09
IL138829A0 (en) 2001-10-31
AU5575099A (en) 2000-03-14
UA72205C2 (uk) 2005-02-15
JP2011021035A (ja) 2011-02-03
ES2393200T3 (es) 2012-12-19
PL201688B1 (pl) 2009-04-30
DE69904918D1 (de) 2003-02-20
PT2266598T (pt) 2017-05-02
DE15152726T1 (de) 2015-12-10
EP2266598B1 (en) 2017-02-22
KR100454207B1 (ko) 2004-10-26
HRP20000755A2 (en) 2001-02-28
DK1769804T3 (da) 2012-10-15
NO20005947L (no) 2000-11-24
DK2907522T3 (en) 2017-10-23
HUP0101594A3 (en) 2002-01-28
EA200001015A1 (ru) 2001-02-26
KR20010072763A (ko) 2001-07-31
HU1200430D0 (hu) 2001-11-28
US6977077B1 (en) 2005-12-20
DE69904918T2 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
TR200003455T2 (tr) Kemik dayanıklılığını ve sertliğini arttırmak ve kırıkları azaltmak için yöntem
ATE255367T1 (de) Marknagelsystem zur frakturheilung bzw. knochenverlängerung
DE69811933D1 (de) Wirbelsäulenimplantat
EA200000563A1 (ru) Способы лечения женщин в постклимактерическом состоянии с применением ультранизких доз эстрогена
TWI345965B (en) Device for bone fixation
IS1724B (is) Aðferð við meðhöndlun á ígræðlingi úr málmi fyrirskurðaðgerð
DK0987998T3 (da) Decellulering af væv
DE69720177D1 (de) Markraumnagel für die Versorgung von Frakturen der Hüfte
IL138673A0 (en) Method and arrangement for determining where to position fixation means
WO2003094835A3 (en) Fgf variants and methods for use thereof
DE602004011083D1 (de) Orthopädische implantat- und knochenschraubenanordnung
MXPA02010452A (es) Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento.
YU7797A (sh) Kombinovana terapija za osteoporozu
ATE319465T1 (de) Therapeutische verwendung von extrakten aus sophora flavescens oder sophora subprostrata
DK1420827T3 (da) 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter
ATE532523T1 (de) Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur
GB0119104D0 (en) Walking aid
AU2003251729A1 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
EP0817781A4 (en) ALKALI METAL FORMOMONETIN AND METHOD FOR MYCORRHIZAL STIMULATION
WO2003059277A3 (en) Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly
CY1118882T1 (el) Μεθοδος αυξησης της οστικης σκληροτητας και ακαμψιας και μειωσης των καταγματων
ATE309269T1 (de) Heterocarpin, ein protein, das humanes ghrh bindet
ATE321528T1 (de) Verwendung von dattelkern-extrakt zur minderung der anzeichen der hautalterung
Dempster Effects of endogenous and exogenous parathyroid hormone (PTH) on the human skeleton
MD1270F1 (en) Method for treatment of the hand navicular bone pseudarthrosis